CD4 þ CD25 þ regulatory T cells (T reg ) impair anti-tumor and anti-viral immunity. As there are higher T reg levels in cancer patients compared with healthy individuals, there is considerable interest in eliminating them or altering their function as part of cancer or viral immunotherapy strategies. The scurfin transcriptional regulator encoded by the member of the forkhead winged helix protein family (FOXP3) is critical for maintaining the functions of T reg . We hypothesized that targeting FOXP3 expression with a novel arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino (PPMO) based antisense would eliminate T reg and enhance the induction of effector T-cell responses. We observed that the PPMO was taken up by activated T cells in vitro and could downregulate FOXP3 expression, which otherwise increases during antigen-specific T-cell activation. Generation of antigenspecific T cells in response to peptide stimulation was enhanced by pre-treatment of peripheral blood mononuclear cells with the FOXP3-targeted PPMO. In summary, modulation of T reg levels using the FOXP3 PPMO antisense-based genomic strategy has the potential to optimize immunotherapy strategies in cancer and viral immunotherapy.
Introduction
Immunotherapy using vaccines to induce effector T-cell responses against cancers and viral infections has demonstrated promising clinical activity recently; however, CD4 þ CD25 þ regulatory T cells (T reg ), 1 which normally prevent uncontrolled proliferation of antigenspecific T cells thereby limiting autoimmunity, 2-4 also impair host immune response against cancer 5, 6 and adaptive responses against some chronic viral infections. 7 Indeed, elevated T reg levels have been identified in the peripheral blood, regional lymph nodes and the tumor microenvironment of cancer patients, and are associated with reduced survival. [8] [9] [10] [11] [12] Lower levels of T reg occur in patients who are better able to control HIV and cytomegalovirus (CMV) infections. 7 Depletion of T reg in animal models 13, 14 and human studies enhances tumor antigen-specific T-cell responses. 15 Similarly, in preclinical models, depletion of T reg enhances anti-viral responses. 16 There are a number of potential strategies for depleting T reg including use of anti-CD25 antibodies and chemotherapeutics such as cyclophosphamide. Our lab and others 15, [17] [18] [19] [20] have reported that denileukin diftitox (ONTAK), a fusion between the active domain of diphtheria toxin and interleukin-2 (IL-2) that is lethal to cells with high CD25 expression, reduces CD4 þ CD25
Hi frequency and enhances immune responses when administered several days before a cancer vaccine. None of these strategies are ideal due to relative lack of specificity. Denileukin diftitox, for example, can also kill activated T cells with temporarily upregulated CD25. The objective in this study was to develop a more specific inhibitor of T reg that would also have clinical applicability.
One hallmark of T reg is expression of the scurfin transcriptional regulator encoded by the member of the forkhead winged helix protein family (FOXP3), a molecule required for both the development and function of T reg . 21, 22 Mice and humans with defects in FOXP3 experience a spectrum of autoimmune phenomena. 21 Inhibition of FOXP3 by a 15-mer synthetic peptide called P60, when given to BALB/c mice immunized with a tumor associated epitope, induced protection against tumor implantation. 23 As such a peptide cannot inhibit all functions of FOXP3, we hypothesized that targeted disruption of FOXP3 with an antisense inhibitor of FOXP3 gene expression would reduce the frequency or function of T reg .
The synthetic antisense phosphorodiamidate morpholino oligomers (PMOs) are structurally similar to RNA, but the phosphodiester linkage is replaced with a neutral phosphorodimaidate linkage and the ribose ring is substituted with a 6-membered morpholine ring. 24 These modifications result in a novel, chemically stable and nuclease-and RNAseH-resistant antisense oligomers. 25 Previously, PMOs have been used to alter gene expression in primary leukocytes, however, for this the cellular membranes needed to be physically or chemically perturbed to facilitate delivery, which can non-specifically decrease cell viability. [26] [27] [28] We have demonstrated that PMO conjugated with cell-penetrating peptides rich in arginine specifically alter gene expression in cultures of primary murine leukocytes, 29 and in a model of murine skin hypersensitivity, peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) was effective in targeting activated T cells, 30 however, the delivery of the PPMO to human leukocytes is not well characterized. In this study, we assessed whether an arginine-rich (RXR) 4 , cell-penetrating, PPMO targeting FOXP3 would inhibit human T reg function and enhance induction of effector T-cell responses.
Materials and methods

Blood collection and cell preparation
Blood products used for obtaining peripheral blood mononuclear cells (PBMCs) were obtained following signed informed consent from cancer patients and healthy human donors according to the Duke University Medical Center institutional review board-approved protocol. For peptide-expanded cultures, donors were tested for the presence of major histocompatibility complex (MHC) class I HLA-A*0201 by genotyping. CMV status was tested using a latex agglutination test (BD Biosciences, San Jose, CA) that detects CMV-specific IgG and IgM.
Quantitative real-time PCR PBMCs isolated from donor blood were stained with CD25-FITC and CD4-PerCP (BD, San Jose, CA) for 30 min at room temperature, washed and sorted by fluorescence-activated cell sorting (FACS) based on expression of CD4 þ CD25 Hi , CD4 þ CD25
Med and CD4 þ CD25À cells. These sorted cell fractions were washed once with phosphate-buffered saline (PBS), and RNA was isolated from B10 5 cells using the RNeasy mini kit along with on-column DNase treatment (Qiagen, Carlsbad, CA). Complementary DNA was produced using oligo(dT) primers and SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA). In all, 0.2 mg of complementary DNA was then used in each 50 ml realtime PCR reaction using TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA). Specific TaqMan assays on demand probe/primer sets were used for both FOXP3 and hypoxanthine ribosyltransferase 1 (HPRT); the sequences for the probes are: 5 0 -6(FAM)-ATCCGCTGGGCCATCCTGGAGGCTC-3 0 (FOXP3) and 5 0 -6(FAM)-GGTCAAGGTCGCAAGCTTGCTGG TG-3 0 (HPRT). Cells transiently transduced with a plasmid expressing human FOXP3 were used as a positive control and the bands produced from real-time PCR were subsequently sequenced using an ABI Prism 3700 detection system (Applied Biosystems) in order to assure specific gene amplification. Real-time PCR was carried out using an ABI Prism 7900 sequence detection system (Applied Biosystems) using the following conditions: 951C for 10 min, followed by 40 cycles at 951C for 30 s and 601C for 30 s. Threshold cycles were then determined using the linear part of the amplification curve and then relative values were calculated from triplicate reactions for each condition. The relative quantity of FOXP3 transcripts is then expressed relative to HPRT with the value for HPRT ¼ 1.
Proliferation assay
PBMCs were sorted by FACS into CD4 þ CD25
Hi and CD4 þ CD25À populations. CD4 þ CD25
Hi cells were cocultured with CD4 þ CD25À cells at a 1:1 ratio in a total volume of 200 ml per well in the 96-well roundbottom plates. CD4 þ CD25À and CD4 þ CD25
Hi were also cultured alone as positive and negative controls. All cell cultures were stimulated with media alone or 0.5 mg ml À1 soluble OKT3 for 96 h. Proliferation was determined by (3H)thymidine (1 mCi per well) incorporation using a Wallac Scintillation Counter (Perkin Elmer, Gaithersburg, MD, USA). Data are reported as mean counts per minute ± s.d.
T reg levels in cancer patients
Based on the identification of CD4 þ CD25
Hi as consistent with T reg populations, we analyzed blood samples from 41 healthy normal volunteers, 78 patients with colon, rectal, kidney, esophageal, liver, pancreatic, gastric, melanoma, or prostate cancer, and in a separate analysis, 26 patients with a breast cancer diagnosis. Patient treatment and tumor characteristics were obtained from review of medical records. Cell surface staining was performed using CD4-PerCP and CD25-FITC (BD) added to 200 ml whole blood, and incubated at room temperature for 45 min. Red blood cells were subsequently lysed using FACS lysing solution (BD Biosciences). Cells were then washed with 1% BSA (bovine serum albumin)/PBA and flow cytometry was performed on a BD FACSCalibur (BD, Franklin Lakes, NJ). All samples were gated for lymphocytes based on forward scatter lo , side scatter lo and CD4 pos populations. Approximately 50 000 total events were collected. The nonparametric Van der Waerden test was used to determine the significance of differences between CD4 þ CD25 Hi populations in normal donors versus cancer patients.
Peptide-conjugated PMO PMOs were synthesized at AVI BioPharma (Corvallis, OR) as described earlier. 24 Purity was 495% as determined by reverse-phase high pressure liquid chromatography and matrix-assisted laser desorption/ionization time-of-flight mass spectrometer. PPMO was produced by attaching the C-terminal cysteine of the peptide (RXR)4 to the 5 0 -end of the PMO through a cross-linker N-(a-maleimidobutyryloxy) succinimide ester (BGBS).
31 PPMO was dissolved in sterile H 2 O before it was used in cell cultures.
The base composition of the oligomers are: FOXP3 PPMO sequence:
Oligomer uptake in immune cells Cryopreserved PBMCs were thawed in RPMI (Sigma, St Louis, MO, USA) supplemented with 10% human AB serum (Sigma), 2 mM L-glutamine (Sigma), 25 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Sigma), and 100 ug ml À1 penicillin and streptomycin (Sigma). Cells were seeded in a 6-well plate (2 Â 10 6 ) in serumcontaining media for 24 h. FITC-labeled scrambled PPMO (2.5 or 5 mM) was added to the cells in serumcontaining media and incubated for 24 h. The treated cells were collected using Cell Dissociation Buffer (Sigma) to release adherent cells and washed (3 Â ) with PBS. Cells (1 Â 10 6 ) were partitioned into a 96-well plate, centrifuged and stained for cell surface markers. Antibody cocktails (BD) were as follows: T cells (CD3 PE, CD4 PerCP, CD8 APC), B cells (CD45 PerCP, CD19 APC) and monocytes (HLA-DR PerCP, CD14 APC). A negative control cocktail was made with IgG isotype control for each color, and propidium iodide was used to determine cell viability. Staining was carried out at room temperature in the dark for 20 min. Cells were then washed (2 Â ) with 1% BSA in PBS and resuspended in 1% BSA in PBS. Flow cytometry was carried out using FACSCalibur (BD) and data were analyzed using the Cell Quest Pro Software (BD, San Jose, CA, USA).
Oligomer uptake in activated T cells
In all, 4 Â 10 6 PBMCs in 1 ml 10% huAB serum/RPMI plus 1 mg ml À1 anti-CD28 were seeded per well in 24-well plates coated with anti-CD3 (OKT3). Uncoated wells were used as non-activated control. Following overnight incubation, a FITC-tagged PMO was added and incubated for 24 h at 37 1C. Cells were harvested, stained (CD4-PE/CD3-PerCP/CD14, CD19-APC) and analyzed by flow cytometry for PMO and PPMO uptake.
FOXP3 expression in activated T cells PBMCs were treated as described above for PPMO uptake. After overnight incubation, cells were harvested, analyzed by flow cytometry for FOXP3 expression using an anti-human FoxP3 Staining set (eBioscience, San Diego, CA) according to the manufacturer's directions. Briefly, cells were stained using anti-CD25-FITC, anti-CD3-PerCP and anti-CD4-APC (BD) for 30 min. Cells were fixed and permeabilized before intracellular staining with anti-Foxp3-PE. Cells were collected using a FACSCalibur (BD) and data were analyzed by CellQuest (BD). The percent CD4 þ CD25 þ FOXP3 þ was determined by gating on the CD4 þ CD25 bright cells that are also 490% FOXP3 þ .
In vitro analysis of antigen-specific T-cell expansion after T reg depletion PBMCs were incubated with media alone or FOXP3 PMO overnight and recovered in 10 U ml À1 IL-2 for 3 days. The cells were then stimulated with 1 mg ml À1 CMV pp65(495-503) peptide at 8 Â 10 6 cells per well in 24-well plates, and 300 U ml À1 IL-2 was added to each well in every 3 days. Stimulated cells were analyzed by peptide-MHC tetramer binding at days 7, 10 and 14. Stimulators were cultured at an 8:1 ratio to responders for the reculture. On day 8 of the reculture, MART-1-expanded cells were analyzed by peptide-MHC tetramer (Beckman Coulter, San Diego, CA) staining. Peptide-MHC tetramer staining was performed using 10 6 cells per tetramer analysis. Cells were stained for 30 min with aCD3-FITC, aCD8-PerCP, aCD4, aCD14, aCD19-APC and tetramer-PE. Tetramer-positive cells were identified by gating on the population of cells that were forward scatter lo side scatter lo CD4ÀCD14ÀCD19ÀCD3 þ .
Results
Confirmation of the role of FOXP3 in T reg
To confirm that the CD4 þ CD25 Hi T cells are consistent with T reg , CD4 þ subsets from human PBMCs were sorted (Figure 1a ) according to CD25 expression (CD4 þ CD25 Hi ¼ B1% of total CD4 þ cells). We assayed FOXP3 mRNA transcript levels from three normal donors and one colon cancer patient using the FACS-sorted CD4 þ subsets, and identified FOXP3 primarily in the CD4 þ CD25
Hi cells (Figure 1b) . Additionally, proliferation assays were performed using the various subsets, and CD4 þ CD25
Hi cells were cocultured with CD4 þ CD25À cells at various ratios in order to determine suppressive capability of this subset (Figure 1c) . We observed that the CD4 þ CD25 Hi T cells caused the greatest suppression of T-cell proliferation. These data confirm that the CD4 þ CD25 Hi T cells are consistent with T reg .
Increased T reg in cancer patients
Using the strategy described above, we gated on the CD4 þ CD25 Hi T cells to enumerate the T reg within peripheral blood of 41 healthy volunteers and 78 patients with various solid tumors (colon, rectal, kidney, esophageal, liver, pancreatic, gastric, melanoma, or prostate cancer), and a separate group of women with breast cancer of different stages (26 breast cancer patients (9 stage I, 8 stage II, 3 stage III, 6 stage IV)). Among the solid tumor group, the magnitude of the CD4 þ CD25 Hi cells was higher in cancer patients (mean 5.93±4.35%, median 5.10%) than normal donors (mean 3.57 ± 1.62%, median 3.35%) (Po0.0001) (Figure 2) . Among breast cancer patients, for those with more advanced disease (higher stage, positive axillary nodal metastases), a greater percentage of T reg was observed (data not shown). These data suggest that T reg accumulate in cancer patients, particularly those with higher stage disease.
Activated T cells exhibit increased FOXP3 expression
As we demonstrated above, FOXP3 expression is identified in resting CD4 þ CD25 Hi T cells. However, we have previously noted that FOXP3 expression increases in T-cell cultures when they have been exposed to IL-2 (unpublished observations). We confirmed these observations in the current study by analyzing FOXP3 expression in unactivated and IL-2-or OKT3-activated T cells. As demonstrated in Figure 3 , OKT3 and IL-2 led to upregulated FOXP3 expression, suggesting that FOXP3 is upregulated irrespective of the mechanism of T-cell activation. Figure 4a show significant uptake of the (RXR) 4 PPMO in cells of immune origin with high bioavailability in T-cell subsets compared with minimal uptake of the unconjugated PMO. In the case of monocytes, both PMO chemistries showed similar uptake. Uptake of the (RXR) 4 -conjugated PMO was also identified to be higher in activated CD4 þ T cells than that of non-activated populations of CD4 þ cells (Figure 4b ). These data suggest that activation of T cells enhances uptake of peptide-conjugated PMO. FOXP3-specific PPMO abrogates increase of CD4 þ CD25 Hi FOXP3 during T-cell activation It is well established that activation of T cells by IL-2 causes an increase in CD25 and FOXP3 expression in CD4 þ T cells. 32, 33 We wished to determine whether 
Peptide conjugation facilitates delivery of PMO into human immune cells Uptake into human immune cells of conjugated morpholino oligomer (PPMO) was compared to that of neutral unconjugated morpholino oligomer (PMO). Data in
CD4 þ CD25
Hi cells exposed to the various PPMOs was determined by flow cytometric analysis. On day 1 (after PMO exposure, but before IL-2), there was no increase in CD4 þ CD25 Hi or CD4 þ CD25 Hi FOXP3 þ T cells. By day 4 (including 3 days of IL-2 exposure), we observed an absolute increase in CD4 þ CD25
Hi T cells in all groups but the increase was 3.3% and 4.3% for the control cells and the scrambled PMO, respectively, whereas the increase was only 0.88% for the FOXP3-specific PPMO (Figure 5a) . We also observed a trend towards a decrease in the CD4 þ CD25 Hi T cells expressing FOXP3 following the application of FOXP3 PPMO (Figure 5b ). These data suggest that the FOXP3-specific PPMO abrogates the increase in T reg that occurs during T-cell activation with IL-2 by reducing FOXP3 expression.
Inhibition of FOXP3 expression with FOXP3-specific PPMO leads to enhanced immune responses We wished to determine whether elimination of FOXP3 þ T cells by FOXP3 PPMO would permit enhanced induction of immune responses. Based on the above results, it was clear that even with the increase in T reg that occurs during bulk T-cell activation, we could reduce the level of T reg with FOXP3 PPMO. Instead of trying to isolate the very limited T reg population (after exposure to PPMO) for a functional assay, we chose a more powerful demonstration of the ability of FOXP3 PPMO to eliminate T reg suppressor function. Specifically, we wished to demonstrate enhanced induction of antigenspecific T cells, when PBMCs were stimulated with antigen (and IL-2) after application of FOXP3 PPMO. We used the activation of the T-cell response against CMV as a model as previously reported. 17 In repeated experiments, we observed an B50% increase in the relative percentage of CMV-specific T cells induced after FOXP3 PPMO exposure ( Figure 6 ) compared with scrambled PPMO. Therefore, eliminating CD4 þ CD25 Hi T reg with FOXP3 PPMO permitted enhanced expansion of antigen-specific effector T cells.
Discussion
A major challenge to the efficacy of cancer and viral vaccines is the modulation of T-cell expansion by inhibitory cells such as T reg . Elevated T reg levels in the peripheral blood, regional lymph nodes and tumor microenvironment of patients with cancer have major functional consequences and are associated with reduced survival.
11-14 T-cell responses against viral infections also appear to be modulated by T reg . 7 Therefore, there has been considerable interest in depleting T reg to enhance anti-tumor and anti-viral immunity, and indeed animal and human studies have suggested that reductions of T reg lead to enhanced anti-tumor immune responses. ), cells were stimulated in vitro with 1 mg ml À1 CMVpp65 peptide plus IL-2 (600 U ml
À1
) for 14 days. T-cell cultures were analyzed by flow cytometry for CMVpp65-specific T cells using CMVpp65 peptide-MHC tetramer. The number of CD8 þ CMVpp65tetramer þ cells per ml of culture is presented for 0, 7, 10, and 14 days following media control and FoxP3 PPMO pre-treatment of PBMCs.
possess persistently high expression of the IL-2 receptor component CD25, a potential strategy for depleting T reg is the use of anti-CD25 antibodies. However, this could be limited by the persistence of the antibodies that would also deplete or inhibit activated T cells that transiently upregulate CD25. Chemotherapeutics have nonspecific toxicity with narrow therapeutic windows. We studied denileukin diftitox (ONTAK), a fusion between the active domain of diphtheria toxin and IL-2 which binds to cells expressing high levels of CD25 whereupon it is internalized, leading to blockade of protein synthesis and cell death. We observed that denileukin diftitox reduced T reg number and function in vitro and in vivo, 17 but the T reg depletion was only about 50-75% complete.
We chose to study morpholino antisense oligomers as the strategy for inhibiting FOXP3 because of the extensive efficacy that they have shown in multiple disease models 25 and safety profile in humans. 34, 35 Unfortunately, morpholino oligomers similar to other gene-silencing technologies are not efficiently taken up by primary leukocytes without use of physical or chemical manipulations. 36, 37 However, in the present study, we were able to confer a dramatic increase in uptake and efficacy of the PMO into human T cells by covalently attaching membrane-penetrating peptides. Pharmacokinetic analysis following a single intravenous dose (15 mg kg À1 ) in rats showed an improvement in kinetic behavior compared with non-conjugated PMO. 38 A twofold increase in PPMO elimination half-life, up to fourfold increase in volume of distribution and increased tissue retention compared with the unconjugated PMO with no apparent signs of toxicity were reported, revealing that the conjugation of the arginine-rich, cell-penetrating peptide is an attractive transporter for PMO delivery and a viable therapeutic option. PPMOs also have shown efficacy against multiple viruses such as influenza virus, West Nile virus, Ebola virus, and members of the Picornaviridae and other bacteria such as Salmonella enterica, Mycobacterium smegmatis and Klebsiella pneumoniae. 39, 40 The successful and widespread use of PMOs for knockdowns in exquisitely sensitive embryonic systems such as zebrafish and Xenopus show that they are attractive human therapeutics. Further, antisense PPMOs are highly specific and are not targets for neutralizing antibody responses, and thus are desirable molecules to use in humans. 31 The present study demonstrates that PPMO antisensemediated targeting of FOXP3 reduces T reg frequency as suggested by the attenuation in the expansion of CD4 þ CD25 bright T cells otherwise seen during the induction of effector immune responses. Although most CD4 þ CD25 bright T cells are T reg cells, there can be transient upregulation of CD25 on activated CD4 þ T cells. Interestingly, we also observed a small decrease in the percentage of CD4 þ CD25 þ T cells, which expressed FOXP3 after the PPMO antisense application. We speculate that this may be evidence of CD4 þ T helper cell activation and expansion during T reg depletion.
An important consequence of the depletion of T reg was the ability to activate a greater frequency of CMV-specific T cells. This has important implications for use of the PPMO in patients with chronic viral infections and suggests that the PPMO may be used to enhance vaccine-induced immune responses as well. Furthermore, because we have shown that other methods of T reg depletion lead to enhanced anti-tumor immune responses to cancer vaccines, we propose that the PPMO may be useful to administer as part of cancer immunotherapy strategies. Indeed, we now propose to study the PPMO in in vivo models of tumor immunotherapy.
